Comprehensive Proposals in the Asian IVD Market and Expansion of the Immunodiagnostics Business
First written in FY2016. 5 of 8 entries say "Advanced", first in FY2019-Q2. Latest entry: FY2024-Q3.
The whole theme swung hardest in 2017: 1 of 6 companies on the "Worse" side.
3 other companies' latest entry also says "Advanced".
- FY2024-Q3AdvancedAnnual report
「December 2023: Domestic reimbursement coverage began for our assay reagent, HISCL M2BPGiTM-Qt Reagent, which can quantitatively assess the progression of liver fibrosis using only blood in the diagnosis and treatment of patients with chronic hepatitis and cirrhosis.」
The HISCL M2BPGi-Qt reagent became eligible for domestic reimbursement, advancing the clinical use of liver fibrosis assessment in chronic hepatitis and cirrhosis. - FY2023AdvancedAnnual report
「In the immunoassay field, we will expand the reagent menu for the fully automated immunoassay analyzers HISCL™-5000/HISCL-800 and promote the early commercialization of a business designed to support the diagnosis of Alzheimer's disease.」
For the immunoassay field, the company identified expansion of the HISCL reagent menu and early commercialization of a business supporting the diagnosis of Alzheimer's disease as specific measures under the new medium-term plan. - FY2020AdvancedAnnual report
「In the immunoassay field, we aim to expand the business by strengthening our market presence through the development of unique items, mainly in the liver disease field, and by increasing the number of approved reagent items, while accelerating the market introduction of reagents, including existing unique items such as the HISCL™ M2BPGi reagent for liver fibrosis testing, alongside an increase in instrument installations in China and Asia.」
In immunoassays, the company specified the development of unique items in the liver disease field, an increase in the number of approvals, more instrument installations in China and Asia, and accelerated market introduction of the HISCL™ M2BPGi reagent and other products. - FY2019-Q3AdvancedAnnual report
「Although instrument sales declined mainly in the hematology and blood coagulation testing fields, reagent sales increased in the blood coagulation testing and immunoassay fields, among other factors, resulting in revenue of ¥54,726 million, up 4.7% year on year.」
In China, reagent sales in the immunoassay field increased, and revenue rose 4.7% year on year, including growth in reagent sales in the blood coagulation testing field. - FY2019-Q2AdvancedAnnual report
「August 2018: We launched the HISCL™ Presepsin Reagent, an assay reagent for presepsin, a key test item for bacterial sepsis, usable with the HISCL™-5000/2000i/800 fully automated immunoassay analyzers in the immunoassay field.」
Launched a presepsin assay reagent for HISCL, expanding the reagent lineup in the immunoassay field. - FY2018RestatedAnnual report
「In the immunoassay field, we will expand our business in Japan, China and Asia by pursuing business expansion in the liver disease area and promoting the market introduction of unique test items in China and Asia. Alongside sales growth, we will work to improve profitability through measures including cost reductions.」
The company reiterated its policy of expanding the liver disease business, introducing unique test items in China and Asia, and expanding its business in Japan, China and Asia. - FY2017RestatedAnnual report
「In the immunoassay field, we will expand our business in Japan, China and Asia by pursuing business expansion in the liver disease area and promoting the market introduction of unique test items in China and Asia.」
The company reiterated its policy of expanding the immunoassay business in Japan, China and Asia and introducing unique test items to the market. - FY2016First statedAnnual report
「Strengthening comprehensive solutions in the Asian IVD market and reinforcing product development and sales and service structures to meet regional needs」
Initiatives to strengthen product development and sales and service structures tailored to regional needs in Asian markets.